Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of Oral PROTAC Drug HP568 Tablets in China

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntary Disclosure of Completing First Subject Enrollment for Clinical Trial of Oral PROTAC Drug HP568 Tablets in China The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A